Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 66.56B 58.18B 53.58B 49.74B 94.56B 6,349B 95.72B 640B 249B 3,110B 250B 244B 10,787B P/E 2026 *
16.9x
P/E 2027 * 13.6x
Enterprise Value 58.69B 51.29B 47.24B 43.85B 83.37B 5,598B 84.39B 565B 220B 2,742B 220B 216B 9,511B EV / Sales 2026 *
3.69x
EV / Sales 2027 * 3.19x
Free-Float
72.33%
Yield 2026 *
0.6%
Yield 2027 * 0.68%
1 day-0.68%
1 week+2.67%
Current month+4.21%
1 month+2.26%
3 months-14.71%
6 months-14.86%
Current year-15.81%
1 week 622.29
Extreme 622.29
657.96
1 month 594.9
Extreme 594.9
657.96
Current year 591.52
Extreme 591.52
821.11
1 year 532.6
Extreme 532.6
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 31/12/2000
Chief Executive Officer 73 07/01/1988
Director of Finance/CFO 55 04/02/2024
Director TitleAgeSince
Chairman 73 08/06/2023
Director/Board Member 85 31/05/1991
Director/Board Member 85 31/05/1991
Date Insider Type Main position Quantity % Market Cap.
04-30Sell

Director

-100 0.0001%
03-31Sell

Director

100 0.0001%
03-01Sell

Director

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%+2.67%+18.72%-9.48% 66.56B
-1.97%-1.59%+50.62%+218.16% 56.51B
-1.13%+40.50%+40.50%+40.50% 42.98B
+1.99%+8.15%-48.83%-54.69% 40.46B
-3.54%-3.50%+56.89%-27.08% 31.91B
+2.56%+21.60%+168.28%-33.79% 31.65B
-1.06%+1.64%+68.91%+83.55% 23.35B
+3.08%+20.43%+4.99%+186.85% 19.46B
+0.21%+2.96%+66.67%+129.01% 17.18B
+0.73%+10.69%+76.74%+344.54% 15.12B
Average -0.23%+9.25%+50.35%+87.76% 34.52B
Weighted average by Cap. -0.54%+7.82%+43.53%+64.61%

Financials

2026 *2027 *
Net sales 15.89B 13.89B 12.79B 11.88B 22.58B 1,516B 22.85B 153B 59.55B 743B 59.68B 58.37B 2,576B 17.58B 15.36B 14.15B 13.14B 24.97B 1,677B 25.28B 169B 65.86B 821B 66.01B 64.56B 2,849B
Net income 4.09B 3.57B 3.29B 3.05B 5.81B 390B 5.88B 39.33B 15.32B 191B 15.35B 15.02B 663B 5.13B 4.49B 4.13B 3.84B 7.29B 490B 7.38B 49.38B 19.23B 240B 19.28B 18.85B 832B
Net Debt -7.88B -6.88B -6.34B -5.89B -11.19B -751B -11.33B -75.76B -29.51B -368B -29.57B -28.93B -1,276B -10.53B -9.2B -8.47B -7.87B -14.95B -1,004B -15.14B -101B -39.44B -492B -39.53B -38.66B -1,706B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
06/07/26 US$649.81 -0.68% 712,937
02/07/26 US$654.27 +4.73% 1,071,604
01/07/26 US$624.72 +0.19% 1,170,657
30/06/26 US$623.54 -1.31% 820,925
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
654.27USD
Average target price
826.52USD
Spread / Average Target
+26.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock